Overview

A Study in Participants With Diabetic Peripheral Neuropathic Pain in China

Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to assess the efficacy of duloxetine 60 milligrams (mg) once daily (QD) compared with placebo, on the change in pain severity from baseline to 12 weeks as measured by the weekly mean of the daily pain scores recorded in the participant's diary in participants with diabetic peripheral neuropathic pain.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Duloxetine Hydrochloride